Abstract:HepatoBiliary Surg Nutr 2020;9(6):794-796 | http://dx.doi.org/10.21037/hbsn.2020.03.24 Liver cancer was ranked the sixth most commonly diagnosed cancer with the fourth leading cause of cancer-related deaths worldwide in 2018 (1). Notably, hepatocellular carcinoma (HCC) constitutes 75–85% among all the liver cancer cases, and ranks first morbidity and mortality of malignancies in Chinese males under 60. Due to hypervascularity in liver and high heterogeneity, HCC was regarded as an aggressive disease. Recent clinical trials focusing on resection and transplantation after targeted therapy for advanced HCC show encouraging results. However, the adjuvant therapy for patients with high risk of recurrence after surgery still raises attention. Currently, emerging evidence suggested that the crosstalk between tumor cells and the microenvironment plays a pivotal role in tumorigenesis and metastasis. The tumor microenvironment of HCC provides tumor cells with necessary conditions for their sustained growth, invasion and metastasis. It is typically characterized by dysregulated immune network, sustained injury and regeneration, angiogenesis, inflammation and metabolic reprogramming. These aforementioned characteristics raise attention to the important role of infiltrating immune cell profile and tumor stroma in microenvironmental regulation. According to the immune cell subset and proportion, HCC could be classified into different immune subtypes, for example, Sia’s “immune class/ exclusion” and Kurebayashi’s “immune high/mid/low”. Zhang et al. further identified three novel distinctive HCC subtypes with immunocompetent, immunodeficient, and immunosuppressive features (2). Immunocompetent and immunosuppressive subtype were characterized by robust immune cell infiltration and upregulated immune checkpoint molecules. These two subtypes, as well as the “immune class” and “immune-high subtype”, displayed significant increase in immune cells infiltration and better responsiveness to immunotherapy. Tumor stroma and vasculature could also cause considerable impact on tumor progression. Cancer-associated fibroblasts (CAFs) can result in a robust stromal reaction characterized by fibrotic extracellular matrix and make tumor cells convert to aggressive and immune-excluded phenotype via transforming growth factor-β (TGF-β) signaling pathway (3). Tumor-associated vasculature is another main hallmark of cancers. Endothelial cells (ECs) of the tumor vasculature can not only inhibit anti-tumor immunity by immune cells regulation and elimination, but also help to create a proangiogenic microenvironment via vascular endothelial growth factor (VEGF) signaling pathway (4). The disorganized tumor vasculature could remodel a special microenvironment characterized by hypoxia, acidosis, and high interstitial pressure, which both support tumor cells proliferation and structure a physical barrier for infiltrating immune cells (5). Furthermore, the interaction between different components relies on the regulation of chemokines and cytokines, which play essential roles in recruiting immune cells and maintaining cancer and stromal cell biology (6). In another word, these microenvironmental populations profoundly influence the tumor immune and metabolic homeostasis, which suggests immunometabolism as a novel perspective of HCC microenvironment. Editorial

Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment

Targeting tumor microenvironment as a treatment strategy for hepatocellular carcinoma

Microenvironment of a Tumor-Organoid System Enhances Hepatocellular Carcinoma Malignancy-Related Hallmarks.

Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: A model system for dual analysis of tumor growth and angiogenesis

Vascular Endothelial Cells Facilitated HCC Invasion and Metastasis Through the Akt and NF-κB Pathways Induced by Paracrine Cytokines

Abstract 4212: Mimicking HCC complex biology and diverse treatment response in a patient-derived microfluidic model

Hepatocellular-Carcinoma-Derived Organoids: Innovation in Cancer Research

An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer

Construction and drug screening of Co-culture system using extrahepatic cholangiocarcinoma organoids and tumor-associated macrophages

The interactions between integrin α5β1 of liver cancer cells and fibronectin of fibroblasts promote tumor growth and angiogenesis

In vitro vascularized liver tumor model based on a microfluidic inverse opal scaffold for immune cell recruitment investigation

Single-cell RNA sequencing reveals cell subpopulations in the tumor microenvironment contributing to hepatocellular carcinoma

Hypoxia‐inducible Factor‐1α/interleukin‐1β Signaling Enhances Hepatoma Epithelial–mesenchymal Transition Through Macrophages in a Hypoxic‐inflammatory Microenvironment

Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma

Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome

Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients

Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma

Cancer‐associated fibroblasts nurture LGR5 marked liver tumor‐initiating cells and promote their tumor formation, growth, and metastasis

Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny

Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms

Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6+ CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma